Clinical Trial

Study to Assess the Safety and Efficacy of ZX-7101A for Oral Suspension in Chinese Pediatric Participants 2 to 11 Years of Age With Influenza

Study acronym: ZX-7101A-214
Completed Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this phase III study is to learn if ZX-7101A for oral suspension works to treat uncomplicated influenza in Pediatric Participants aged 2 to 11 years. The main question it aims to answer is: What medical problems do participants have when taking drug ZX-7101A for oral suspension or Oseltamivir phosphate for oral suspension? Researchers will compare drug ZX-7101A for oral suspension to active comparator: Oseltamivir phosphate for oral suspension to see if drug ZX-7101A for oral suspension works to treat uncomplicated influenza in Pediatric Participants aged 2 to 11 years.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-30; most recent amendment 2026-04-14.
Status change: Recruiting → Completed 2026-04-14
Status change: Not Yet Recruiting → Recruiting 2025-11-16
Trial Details
NCT Number NCT07095257
Lead Sponsor Nanjing Zenshine Pharmaceuticals
Conditions Respiratory Viral Infection
Enrollment 169 participants
Start Date 2025-10-13
Primary Completion 2026-01-16 (estimated)
Study Completion 2026-01-16 (estimated)
Updated on ClinicalTrials.gov 2026-04-16